Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Renal Cell 2 Carcinoma, Non-Small-Cell Lung 2 Triple Negative Breast Neoplasms 1 Ovarian Neoplasms 1 Melanoma 1 Colorectal Neoplasms 1

Interventions

Carboplatin 44 Paclitaxel 43 liposomal doxorubicin 23 Topotecan 19 Gemcitabine 18 pembrolizumab 17 Cyclophosphamide 17 Bevacizumab 16 Cisplatin 12 niraparib 9 olaparib 8 fludarabine 7 Taxes 7 Docetaxel 7 aldesleukin 6 Nivolumab 6 Doxorubicin 6 1-dodecylpyridoxal 6 oregovomab 5 fludarabine phosphate 5 Peripheral Blood Stem Cell Transplantation 5 Filgrastim 5 rucaparib 4 durvalumab 4 avelumab 4 Surgical Procedures, Operative 4 Melphalan 4 Ipilimumab 4 Interleukin-2 4 Etoposide 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Ovarian Neoplasms × CB-839 × Clear all

NCT03944902 2023-11-21

BRCA

University of Alabama at Birmingham

Phase 1 Terminated

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡